DAFTAR PUSTAKA

Allen, L., and Ansel, H. C.2013. Ansel's pharmaceutical dosage forms and drug delivery systems. Lippincott Williams & Wilkins.

AlTuraifi, F. H. *et al.* 2019. Assessment of Microbiological Content of Private and Public Recreational Water Facilities and Their Antimicrobial Susceptibility Pattern in Al-Ahsa. Environmental Health Insights, 13, 1178630219887393.

Austin, A., Lietman, T., Rose-Nussbaumer, J., 2017. Update on the Management of Infectious Keratitis. Ophthalmology 124, 1678–1689.

Brunton, L.L., Lazo, J.S., Parker, K.L., 2006. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. McGraw-Hill Companies, Inc., United States of America.

Chavan, P.M., Vyas, S., 2017. A Novel Approach In-Situ Gel for Sustained Drug Delivery : A Review. Int. J. Pharm. Pharm. Res. 9.

BPOM. 2015. Peraturan Kepala Badan Pengawas Obat Dan Makanan Republik Indonesia Nomor 5 Tahun 2015 Tentang Pedoman Cara Ritel Pangan Yang Baik Di Pasar Tradisional. Jakarta: BPOM

Dhaval, M., Devani, J., Parmar, R., Soniwala, M.M., Chavda, J., 2020. Formulation and optimization of microemulsion based sparfloxacin in-situ gel for ocular delivery: In vitro and *ex vivo* characterization. J. Drug Deliv. Sci. Technol. 55, 101373.

Donnelly, R.F., 2011. Stability of cefazolin sodium in polypropylene syringes and polyvinylchloride minibags. Can. J. Hosp. Pharm. 64, 241–245.

Ezisi, C.N., Ogbonnaya, C.E., Okoye, O., Ezeanosike, E., Ginger-Eke, H., Arinze, O.C., 2018. Microbial Keratitis—A Review of Epidemiology, Pathogenesis, Ocular Manifestations, and Management. Niger. J. Ophthalmol. 26, 13–23.

Elsahn, A., Cendra, M. del M., Humbert, M.V., Christodoulides, M., Dua, H., Hossain, P., 2020. Pseudomonas aeruginosa host-pathogen interactions in human corneal infection models. J. EuCornea.

Gupta, C., Juyal, V. and Nagaich, U. 2018. Formulation and optimization of thermosensitive in-situ gel of moxifloxacin hydrochloride for ocular drug delivery, *International Journal of Applied Pharmaceutics*, 10(3),

pp. 123–130. doi: 10.22159/ijap.2018v10i3.25083.

Güven, U.M., Berkman, M.S., Şenel, B., Yazan, Y., 2019. Development and in vitro/in vivo evaluation of thermo-sensitive in Situ Gelling Systems for Ocular Allergy. Brazilian J. Pharm. Sci. 55, 1–11.

Jain, D. *et al.* 2016. Newer Trends in In Situ Gelling Systems for Controlled Ocular Drug Delivery, *Journal of Analytical & Pharmaceutical Research*, 2(3), pp. 1–16. doi: 10.15406/japlr.2016.02.00022.

Jones, D.S., 2008. FASTtrack: Pharmaceutics - Dosage Form and Design. Pharmaceutical Press, London.

Khattab, A., Marzok, S., Ibrahim, M., 2019. Development of optimized mucoadhesive thermosensitive pluronic based in situ gel for controlled delivery of Latanoprost: Antiglaucoma efficacy and stability approaches. J. Drug Deliv. Sci. Technol. 53, 101134.

Kodym, A., Bilski, P., Domańska, A., Hełminiak, Ł., Jabłońska, M., Jachymska, A., 2012. Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method. Acta Pol. Pharm. - Drug Res. 69, 95–105.

Kodym, A., Zawisza, T., Buźka, K., & Kukuła, H. 2006. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing cefazolin. *Acta poloniae pharmaceutica*, *63*(3), 225.

Lieberman, Rieger & Banker, 1989. Pharmaceutical Dosage Form : Disperse System, Vol ke-3, 495-498, Marcel Dekker Inc, New York.

Madan, J., Adokar, B., Dua, K., 2015. Development and evaluation of in situ gel of pregabalin. Int. J. Pharm. Investig. 5, 226.

Madhu, S. N., Jha, K. K., Karthyayani, A. P., & Gajjar, D. U. 2018. Ex vivo caprine model to study virulence factors in keratitis. *Journal of ophthalmic & vision research*, *13*(4), 383.

Majeed, A., Khan, N.A., 2019. Ocular in situ gel: An overview. J. Drug Deliv. Ther. 9, 337-347.

Marlo, T. L. *et al.* 2017 Development of a novel *ex vivo* equine corneal model, *Veterinary Ophthalmology*, 20 (4), pp. 288–293. doi: 10.1111/vop.12415.

McEvoy, G. K. 2004. *AHFS Drug Information 2004*. Amer Soc of Health System.

Mundada, A.S., Avari, J.G., 2009. In situ gelling polymers in ocular drug delivery systems: A review. Crit. Rev. Ther. Drug Carrier Syst. 26, 85–118.

Mohanty, D., Bakshi, V., Simharaju, N., Haque, M.A., Sahoo, C.K., 2018. A Review on in situ Gel: A Novel Drug Delivery System Dibyalochan. Int. J. Pharm. Sci. Rev. Res. 50, 175–181.

Permana, A. D., Mir, M., Utomo, E., & Donnelly, R. F. 2020. Bacterially sensitive nanoparticle-based dissolving microneedles of doxycycline for enhanced treatment of bacterial biofilm skin infection: A proof of concept study. International Journal of Pharmaceutics: X, 2, 100047. doi:10.1016/j.ijpx.2020.100047

Pinnock, A., Shivshetty, N., Roy, S., Rimmer, S., Douglas, I., MacNeil, S., & Garg, P. 2017. Ex vivo rabbit and human corneas as models for bacterial and fungal keratitis. *Graefe's Archive for Clinical and Experimental Ophthalmology*, *255*(2), 333-342.

Plumb, D. C. 2018. *Plumb's Veterinary Drug Handbook: Desk*. John Wiley & Sons.

Power, D. A., & Johnson, J. A. 2009. Difco™ & BBL™ manual. *Manual of Microbiological Culture Media*, 359-60.

Ratprasatporn, N., Wittayalertpanya, S., Khemsri, W., Chatsuwan, T., Chongpison, Y., Chamsai, T., Chansangpetch, S. 2019. Stability and Sterility of Extemporaneously Prepared Nonpreserved Cefazolin, Ceftazidime, Vancomycin, Amphotericin B, and Methylprednisolone Eye Drops. Cornea, 38(8), 1017–1022. doi:10.1097/ico.0000000000001992

Rojanarata, T., Tankul, J., Woranaipinich, C., Potawanich, P., Plianwong, S., Sakulma, S., & Saehuan, C. 2010. Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives. *Journal of ocular pharmacology and therapeutics*, *26*(5), 485-490.

Rowe, R.C., Sheskey, P.J., Quinn, M.E. (Eds.), 2009. Handbook of Pharmaceutical Excipients, 6th ed. Pharmaceutical Press and American Pharmacists Association, London.

Sarada, K., Firoz, S., Padmini, K., 2015. In-situ gelling system: A review. Int. J. Curr. Pharm. Rev. Res. 5, 76–90.

Soliman, K.A., Ullah, K., Shah, A., Jones, D.S., Singh, T.R.R., 2019. Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications. Drug Discov. Today 24, 1575–1586.

Steffen, G. S., & Candelaria, S. M. 2010. *Drug Interdiction: Partnerships, Legal Principles, and Investigative Methodologies for Law Enforcement*. CRC Press.

Swarbick, J., 2007. Encyclopedia of Pharmaceutical Technology, 3rd ed. Informa Healthcare USA, Inc., New York.

Sweetman, S.C., 2009. Martindale: The Complete Drug Reference, 36th ed. Pharmaceutical Press, London.

Snyder, Katherine, and Chris Keegan. 2016. Pharmacology for the surgical technologist. Elsevier Health Sciences.

Thomas, P., Sekhar, A. C., Upreti, R., Mujawar, M. M., & Pasha, S. S. (2015). Optimization of single plate-serial dilution spotting (SP-SDS) with sample anchoring as an assured method for bacterial and yeast cfu enumeration and single colony isolation from diverse samples. Biotechnology Reports, 8, 45–55. doi:10.1016/j.btre.2015.08.003

Troy, D., 2005. *Remington The Science and Practice of Pharmacy, 21st ed.* Lippincott Williams & Wilkins, a Wolters Kluwer Company, Philadelphia.

Tuany. 2020. Formulasi Dan Karakterisasi Gel Mata *Thermosensitive* Dari *Cefazoline.* Skripsi tidak diterbitkan. Makassar. Fakultas Farmasi Unhas.

Ubani-Ukoma, U. *et al.* 2020. An *ex vivo* cornea infection model, *MethodsX*. Elsevier B.V., 7. doi: 10.1016/j.mex.2020.100876.

Ubani-Ukoma, U. *et al.* 2019. Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an *ex vivo* corneal model, *International Journal of Pharmaceutics*. Elsevier, 565(May), pp. 499–508. doi: 10.1016/j.ijpharm.2019.05.031.

Ung, L., Bispo, P.J.M., Shanbhag, S.S., Gilmore, M.S., Chodosh, J., 2019. The persistent dilemma of microbial keratitis: Global burden, diagnosis, and antimicrobial resistance. Surv. Ophthalmol. 64, 255–271.

Valiev, A. K., Zdoryk, A. A., & Georgiyants, V. A. 2015. Chemical Stability of Pharmacy-Compounded Cefazolin Sodium Eye Drops. Pharmaceutical Chemistry Journal, 48(11), 759–761. doi:10.1007/s11094-015-1188-x

Wadetwar, R. N., Agrawal, A. R., & Kanojiya, P. S. 2020. In situ gel containing Bimatoprost solid lipid nanoparticles for ocular delivery: In-vitro and ex-vivo evaluation. *Journal of Drug Delivery Science and Technology*, *56*, 101575.

Wong, R.L.M., Gangwani, R.A., Yu, L.W.H., Lai, J.S.M., 2012. New treatments for bacterial keratitis. J. Ophthalmol. 2012, 1–7.

Zhu, H. *et al.* 2017. Antimicrobial blue light therapy for infectious keratitis: *Ex vivo* and in vivo studies, *Investigative Ophthalmology and Visual Science*, 58(1), pp. 586–593. doi: 10.1167/iovs.16-20272.

LAMPIRAN

Lampiran 1. Skema kerja penelitian



Lampiran 2. Pembuatan kurva baku



Gambar 17. Kurva baku cefazolin

Tabel 2. Luas area

Konsentrasi	Area 1	Area 2	Area 3	Rata-rata
0.5	189.80	186.00	214.47	196.76 ± 15.46
1	365.00	357.70	412.45	378.38 ± 29.73
2	722.70	708.25	816.65	749.20 ± 58.86
4	1452.63	1423.57	1641.47	1505.89 ± 118.31
8	2890.73	2832.91	3266.52	2996.72 ± 235.44
16	5839.27	5722.48	6598.38	6053.38 ± 475.58
32	11912.11	11673.87	13460.69	12348.89 ± 970.19

Persamaan kurva baku

$Y = ax + b$

$y = 385,12x – 28,228$

$a = 385,12$

$b = -28,228$

$R^2 = 0,9999$

Lampiran 3. Gambar penelitian



Gambar 18. Kromatogram HPLC cefazolin

Gambar 19. Kornea mata babi

Gambar 20. Aparatus cell difusi Franz



Gambar 21. Hasil perhitungan ALT pada kontrol (tetes mata) sebelum penyimpanan (atas) dan setelah penyimpanan (bawah)



Gambar 22. Hasil perhitungan ALT pada formula gel in situ sebelum penyimpanan (atas) dan setelah penyimpanan (bawah)



Gambar 23. Hasil perhitungan ALT jumlah koloni awal



Gambar 24. Hasil perhitungan ALT kontrol

Lampiran 4 Tabel hasil pengujian

Tabel 3.1 Hasil uji suhu gelasi penyimpanan suhu 4°C

Replikasi	Suhu Gelasi (°C)							
	AWAL	Hari-1	Hari-3	Hari-5	Hari-7	Hari-14	Hari-21	Hari-28
1	36,00	36,00	37,00	36,00	36,00	37,00	37,00	36,00
2	37,00	35,00	36,00	35,00	36,00	36,00	37,00	36,00
3	37,00	36,00	36,00	35,00	36,00	36,00	36,00	37,00
Rata-rata	36,67±0,58	35,67±0,58	36,33±0,58	35,33±0,58	36,00±0	36,33±0,58	36,67±0,58	36,33±0,58

Tabel 3.2 Hasil uji suhu gelasi penyimpanan suhu 25°C

Replikasi	Suhu Gelasi (°C)							
	AWAL	Hari-1	Hari-3	Hari-5	Hari-7	Hari-14	Hari-21	Hari-28
1	36,00	37,00	36,00	37,00	37,00	36,00	36,00	36,00
2	37,00	37,00	35,00	36,00	36,00	35,00	36,00	36,00
3	37,00	36,00	35,00	36,00	36,00	36,00	37,00	36,00
Rata-rata	36,67±0,58	36,67±0,58	35,33±0,58	36,33±0,58	36,33±0,58	35,67±0,58	36,33±0,58	36,00±0,00

Tabel 4.1 Hasil uji pH penyimpanan suhu 4°C

Replikasi	pH							
	AWAL	Hari-1	Hari-3	Hari-5	Hari-7	Hari-14	Hari-21	Hari-28
1	4,74	4,71	4,73	4,75	4,73	4,74	4,71	4,73
2	4,69	4,70	4,74	4,69	4,73	4,72	4,73	4,74
3	4,72	4,73	4,72	4,73	4,72	4,73	4,73	4,72
Rata-rata	4,72±0,03	4,71±0,02	4,73±0,01	4,72±0,03	4,73±0,01	4,73±0,01	4,72±0,01	4,73±0,01

Tabel 4.2 Hasil uji pH penyimpanan suhu 25°C

Replikasi	pH							
	AWAL	Hari-1	Hari-3	Hari-5	Hari-7	Hari-14	Hari-21	Hari-28
1	4,74	4,70	4,72	4,73	4,74	4,72	4,70	4,72
2	4,69	4,72	4,73	4,71	4,68	4,73	4,69	4,72
3	4,72	4,74	4,73	4,74	4,74	4,73	4,74	4,73
Rata-rata	4,72±0,03	4,72±0,02	4,73±0,01	4,73±0,02	4,72±0,03	4,73±0,01	4,71±0,03	4,72±0,01

Tabel 5.1 Hasil uji kandungan obat penyimpanan suhu 4°C

Hari	AREA	Konsentrasi (ug/ml)	Drug content (%)	Rata-rata
AWAL	6811	17,76	101,48	100,36±0,98
	6706	17,49	99,92	
	6689	17,44	99,67	
1	6654	17,35	99,15	99,56±0,63
	6730	17,55	100,28	
	6660	17,37	99,24	
3	6741	17,58	100,44	99,88±0,97
	6741	17,58	100,44	
	6627	17,28	98,75	
5	6615	17,25	98,57	99,49±0,82
	6723	17,53	100,17	
	6692	17,45	9971	
7	6694	17,46	99,75	99,65±0,34
	6707	17,49	99,94	
	6663	17,37	99,28	
14	6622	17,27	98,68	99,84±1,59
	6822	17,79	101,65	
	6657	17,36	99,19	
21	6616	17,25	98,59	99,95±1,26
	6722	17,53	100,16	
	6785	17,69	101,09	
28	6763	17,63	100,76	99,67±1,04
	6624	17,27	98,70	
	6681	17,42	99,55	

Tabel 5.2 Hasil uji kandungan obat penyimpanan suhu 25°C

Hari	AREA	Konsentrasi (ug/ml)	Drug content (%)	Rata-rata
AWAL	6811	17,76	101,48	100,36±0,98
	6706	17,49	99,92	
	6689	17,44	99,67	
1	6635	17,30	98,87	100,04±1,02
	6744	17,58	100,48	
	6763	17,63	100,76	
3	6702	17,48	99,86	100,37±0,47
	6764	17,64	100,79	
	6742	17,58	100,46	
5	6665	17,38	99,32	99,37±0,55
	6708	17,49	99,95	
	6634	17,30	98,84	
7	5491	14,33	81,89	82,65±0,68
	5580	14,56	83,22	
	5554	14,50	82,83	
14	3507	9,18	52,45	53,17±0,67
	3563	9,32	53,28	
	3596	9,41	53,77	
21	3046	7,98	45,62	46,15±0,73
	3138	8,22	46,98	
	3062	8,02	45,85	
28	2391	6,28	35,89	35,29±0,59
	2311	6,08	34,71	
	2348	6,17	35,25	

Rumus =

Kandungan obat = $\frac{\text{Konsentrasi (ug/ml)}}{\text{17,5 ug/ml}}$ x 100%

Perhitungan =

Kandungan obat = $\frac{\text{17,74 ug/ml}}{\text{17,5 ug/ml}}$ x 100%

Kandungan obat = 101,34%

Tabel 6.1 Hasil uji viskositas penyimpanan suhu 4°C

Replikasi	Viskositas (cps)							
	AWAL		Hari-1		Hari-3		Hari-5	
	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi
1	201,00	28400,00	218,00	32100,00	220,00	30400,00	210,00	32200,00
2	221,00	30200,00	220,00	28800,00	206,00	29400,00	208,00	28800,00
3	204,00	31200,00	210,00	29800,00	210,00	32100,00	222,00	32200,00
Rata-rata	208,67 ±10,79	29933,33 ±1418,92	216,00 ±5,29	30233,33 ±1692,14	212,00 ±7,21	30633,33 ±1365,04	213,33 ±7,57	31066,67 ±1962,99

Replikasi	Viskositas (cps)							
	Hari-7		Hari-14		Hari-21		Hari-28	
	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi
1	208,00	32400,00	210,00	31800,00	210,00	31200,00	218,00	30600,00
2	212,00	34200,00	220,00	29400,00	205,00	28600,00	210,00	28800,00
3	210,00	29800,00	208,00	31600,00	218,00	30800,00	220,00	30200,00
Rata-rata	210,00 ±2,00	32133,33 ±2212,09	212,67 ±6,43	30933,33 ±1400,00	211,00 ±6,56	30200,00 ±1400,00	216,00 ±5,29	29866,67 ±945,16

Tabel 6.2 Hasil uji viskositas penyimpanan suhu 25°C

Replikasi	Viskositas (cps)							
	AWAL		Hari-1		Hari-3		Hari-5	
	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi
1	201,00	28400,00	208,00	32000,00	208,00	31000,00	216,00	31900,00
2	221,00	30200,00	210,00	28900,00	207,00	28700,00	222,00	28900,00
3	204,00	31200,00	220,00	32100,00	216,00	30700,00	208,00	29700,00
Rata-rata	208,67 ±10,79	29933,33 ±1418,92	212,67 ±6,43	31000,00 ±1819,34	210,33 ±4,93	30133,33 ±1250,33	215,33 ±7,02	30166,67 ±1553,49

Replikasi	Viskositas (cps)							
	Hari-7		Hari-14		Hari-21		Hari-28	
	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi	Sebelum Gelasi	Sesudah Gelasi
1	218,00	30200,00	216,00	30400,00	208,00	31600,00	206,00	32200,00
2	208,00	29500,00	212,00	28900,00	222,00	29500,00	214,00	34300,00
3	208,00	32000,00	218,00	30100,00	206,00	31500,00	208,00	29700,00
Rata-rata	211,33 ±5,77	30566,67 ±1289,70	215,33 ±3,06	29800,00 ±793,73	212,00 ±8,72	30866,67 ±1184,62	209,33 ±4,16	32066,67 ±2302,90

Tabel 7 Hasil uji aktivitas antibakteri

Replikasi	Jumlah Bakteri (cfu/ml)					
	Tetes mata sebelum penyimpanan	**Tetes mata setelah penyimpanan**	**Gel *in situ* sebelum penyimpanan**	**Gel *in situ* setelah penyimpanan**	**Kontrol**	**Koloni Awal**
1	$2{,}4 \times 10^7$	$3{,}0 \times 10^7$	0	0	$3{,}0 \times 10^9$	$2{,}6 \times 10^9$
2	$2{,}5 \times 10^7$	$2{,}4 \times 10^7$	0	0	$2{,}8 \times 10^9$	$2{,}7 \times 10^9$
3	$2{,}6 \times 10^7$	$2{,}4 \times 10^7$	0	0	$3{,}0 \times 10^9$	$2{,}8 \times 10^9$
Rata-rata	$2{,}5 \times 10^7 \pm 1{,}0 \times 10^6$	$2{,}6 \times 10^7 \pm 3{,}3 \times 10^6$	0	0	$2{,}9 \times 10^9 \pm 1{,}2 \times 10^8$	$2{,}7 \times 10^9 \pm 1{,}3 \times 10^8$

Lampiran 5. Hasil analisis statistika

1. Evaluasi suhu gelasi

(a) Penyimpanan 4°C

Test Statistics[a]

N	3
Chi-Square	10.662
Df	7
Asymp. Sig.	.154

a. Friedman Test

(b) Penyimpanan 25°C

Test Statistics[a]

N	3
Chi-Square	10.662
Df	7
Asymp. Sig.	.154

a. Friedman Test

(c) Hari Ke-1

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Gelasi	Equal variances assumed	.000	1.000	-2.121	4	.101	-1.000	.471	-2.309	.309
	Equal variances not assumed			-2.121	4.000	.101	-1.000	.471	-2.309	.309

(d) Hari Ke-3

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Gelasi	Equal variances assumed	.000	1.000	2.121	4	.101	1.000	.471	-.309	2.309
	Equal variances not assumed			2.121	4.000	.101	1.000	.471	-.309	2.309

(e) Hari Ke-5

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Gelasi	Equal variances assumed	.000	1.000	-2.121	4	.101	-1.000	.471	-2.309	.309
	Equal variances not assumed			-2.121	4.000	.101	-1.000	.471	-2.309	.309

(f) Hari Ke-7

Test Statistics[a]

	Gelasi
Mann-Whitney U	3.000
Wilcoxon W	9.000
Z	-1.000
Asymp. Sig. (2-tailed)	.317
Exact Sig. [2*(1-tailed Sig.)]	.700[b]

(g) Hari Ke-14

Test Statistics[a]

	Gelasi
Mann-Whitney U	4.500
Wilcoxon W	10.500
Z	.000
Asymp. Sig. (2-tailed)	1.000
Exact Sig. [2*(1-tailed Sig.)]	1.000[b]

(h) Hari Ke-21

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Gelasi	Equal variances assumed	.000	1.000	.707	4	.519	.333	.471	-.975	1.642
	Equal variances not assumed			.707	4.000	.519	.333	.471	-.975	1.642

(i) Hari Ke-28

Test Statistics[a]

	Gelasi
Mann-Whitney U	3.000
Wilcoxon W	9.000

Z	-1.000
Asymp. Sig. (2-tailed)	.317
Exact Sig. [2*(1-tailed Sig.)]	.700[b]

2. Evaluasi pH

(a) Penyimpanan 4°C

Test Statistics[a]

N	3
Chi-Square	2.291
Df	7
Asymp. Sig.	.942

a. Friedman Test

(b) Penyimpanan 25°C

Test Statistics[a]

N	3
Chi-Square	1.803
Df	7
Asymp. Sig.	.970

a. Friedman Test

(c) Hari Ke-1

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
pH	Equal variances assumed	.400	.561	.500	4	.643	.00333	.00667	-.01518	.02184
	Equal variances not assumed			.500	3.200	.649	.00333	.00667	-.01715	.02382

(d) Hari Ke-3

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
pH	Equal variances assumed	.400	.561	.500	4	.643	.00333	.00667	-.01518	.02184
	Equal variances not assumed			.500	3.200	.649	.00333	.00667	-.01715	.02382

(e) Hari Ke-5

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
pH	Equal variances assumed	1.538	.283	-.169	4	.874	-.00333	.01972	-.05809	.05142
	Equal variances not assumed			-.169	2.941	.877	-.00333	.01972	-.06681	.06014

(f) Hari Ke-7

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
pH	Equal variances assumed	10.811	.030	.329	4	.759	.00667	.02028	-.04963	.06296
	Equal variances not assumed			.329	2.111	.772	.00667	.02028	-.07632	.08965

(g) Hari Ke-14

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
pH	Equal variances assumed	.400	.561	.500	4	.643	.00333	.00667	-.01518	.02184
	Equal variances not assumed			.500	3.200	.649	.00333	.00667	-.01715	.02382

(h) Hari Ke-21

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
pH	Equal variances assumed	3.226	.147	.800	4	.469	.01333	.01667	-.03294	.05961
	Equal variances not assumed			.800	2.735	.487	.01333	.01667	-.04273	.06940

(i) Hari Ke-28

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
pH	Equal variances assumed	.400	.561	1.000	4	.374	.00667	.00667	-.01184	.02518
	Equal variances not assumed			1.000	3.200	.387	.00667	.00667	-.01382	.02715

3. Evaluasi viskositas

(a) Sebelum gelasi penyimpanan 4°C

Test Statistics[a]

N	3
Chi-Square	3.269
Df	7
Asymp. Sig.	.859

a. Friedman Test

(b) Setelah gelasi penyimpanan 4°C

Test Statistics[a]

N	3
Chi-Square	5.463
Df	7
Asymp. Sig.	.604

a. Friedman Test

(c) Sebelum gelasi penyimpanan 25°C

Test Statistics[a]

N	3
Chi-Square	4.715
Df	7
Asymp. Sig.	.695

a. Friedman Test

(d) Setelah gelasi penyimpanan 25°C

Test Statistics[a]

N	3
Chi-Square	5.463
Df	7
Asymp. Sig.	.604

a. Friedman Test

(e) Sebelum gelasi

1. Hari Ke-1

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	.250	.643	.693	4
	Equal variances not assumed			.693	3.857

2. Hari Ke-3

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	.592	.485	.330	4
	Equal variances not assumed			.330	3.536

3. Hari Ke-5

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	.114	.752	-.335	4
	Equal variances not assumed			-.335	3.978

4. Hari Ke-7

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df

Viskositas	Equal variances assumed	5.765	.074	-.378	4
	Equal variances not assumed			-.378	2.473

5. Hari Ke-14

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	2.880	.165	-.649	4
	Equal variances not assumed			-.649	2.859

6. Hari Ke-21

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	.176	.696	-.630	4
	Equal variances not assumed			-.630	3.893

7. Hari Ke-28

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	Df
Viskositas	Equal variances assumed	1.322	.314	-1.531	4
	Equal variances not assumed			-1.531	2.655

(f) Setelah gelasi

1. Hari Ke-1

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	.080	.792	-.534	4
	Equal variances not assumed			-.534	3.979

2. Hari Ke-3

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	.002	.963	.468	4
	Equal variances not assumed			.468	3.970

3. Hari Ke-5

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Viskositas	Equal variances assumed	.452	.538	.623	4
	Equal variances not assumed			.623	3.799

4. Hari Ke-7

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	Df

Viskositas	Equal variances assumed	.693	.452	1.060	4
	Equal variances not assumed			1.060	3.219

5. Hari Ke-14

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	Df
Viskositas	Equal variances assumed	1.807	.250	1.266	4
	Equal variances not assumed			1.266	3.262

6. Hari Ke-21

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	Df
Viskositas	Equal variances assumed	.610	.478	-.159	4
	Equal variances not assumed			-.159	3.714

7. Hari Ke-28

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	T	df
Viskositas	Equal variances assumed	.348	.587	1.715	4
	Equal variances not assumed			1.715	3.790

4. Pengukuran kandungan obat

(a) Penyimpanan 25°C

Test Statistics[a]

N	3
Chi-Square	19.222
Df	7
Asymp. Sig.	.008

a. Friedman Test

(b) Penyimpanan 4°C

Test Statistics[a]

N	3
Chi-Square	.556
Df	7
Asymp. Sig.	.999

a. Friedman Test

(c) Hari ke-1

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Kadar	Equal variances assumed	1.467	.293	-.694	4	.526	-.48000	.69158	-2.40015	1.44015
	Equal variances not assumed			-.694	3.326	.533	-.48000	.69158	-2.56382	1.60382

(d) Hari ke-3

Test Statistics[a]

	Kadar
Mann-Whitney U	2.000
Wilcoxon W	8.000
Z	-1.107
Asymp. Sig. (2-tailed)	.268
Exact Sig. [2*(1-tailed Sig.)]	.400[b]

(e) Hari ke-5

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Kadar	Equal variances assumed	.712	.446	.197	4	.853	.11333	.57400	-1.48035	1.70702
	Equal variances not assumed			.197	3.512	.854	.11333	.57400	-1.57170	1.79836

(f) Hari ke-7

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Kadar	Equal variances assumed	1.806	.250	38.590	4	.000	17.01000	.44078	15.78619	18.23381
	Equal variances not assumed			38.590	2.931	.000	17.01000	.44078	15.58837	18.43163

(g) Hari ke-14

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Kadar	Equal variances assumed	3.615	.130	46.930	4	.000	46.67333	.99454	43.91205	49.43462
	Equal variances not assumed			46.930	2.685	.000	46.67333	.99454	43.28729	50.05937

(h) Hari ke-21

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Kadar	Equal variances assumed	.840	.411	63.897	4	.000	53.79667	.84193	51.45910	56.13424
	Equal variances not assumed			63.897	3.196	.000	53.79667	.84193	51.20780	56.38553

(r) Hari ke-28

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Kadar	Equal variances assumed	.813	.418	93.565	4	.000	64.38667	.68815	62.47607	66.29727
	Equal variances not assumed			93.565	3.178	.000	64.38667	.68815	62.26430	66.50904

5. Uji aktivitas antibakteri

1. Efektivitas antibakteri sebelum dan setelah 28 hari penyimpanan

Test Statistics[a]

	Kontrol tetes mata setelah penyimpanan - kontrol tetes mata sebelum penyimpanan	Formula gel *in situ* setelah penyimpanan - Formula gel *in situ* sebelum penyimpanan
Z	.000[b]	.000[b]
Asymp. Sig. (2-tailed)	1.000	1.000

a. Wilcoxon Signed Ranks Test

b. The sum of negative ranks equals the sum of positive ranks.

2. Efektivitas antibakteri antara formula gel *in situ* dan kontrol

Test Statisticsa,b

	Koloni
Kruskal-Wallis H	14.813
Df	5
Asymp. Sig.	.011

Lanjutan Post Hoc *Kruskal Wallis*

Pairwise Comparisons of Formula

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Gel *in situ* Sebelum Penyimpanan- kontrol tetes mata Sebelum Penyimpanan	6.000	4.273	1.404	.160	1.000
Gel *in situ* Setelah Penyimpanan-kontrol tetes mata Sebelum Penyimpanan	6.000	4.273	1.404	.160	1.000

Gel *in situ* Sebelum Penyimpanan-kontrol tetes mata Setelah Penyimpanan	6.000	4.273	1.404	.160	1.000
Gel *in situ* Setelah Penyimpanan-kontrol tetes mata Setelah Penyimpanan	6.000	4.273	1.404	.160	1.000
Gel *in situ* Sebelum Penyimpanan- Gel *in situ* Setelah Penyimpanan	.000	4.273	.000	1.000	1.000
Gel *in situ* Sebelum Penyimpanan-Koloni Awal	-10.667	4.273	-2.497	.013	.188
Gel *in situ* Sebelum Penyimpanan-Kontrol	-13.333	4.273	-3.121	.002	.027
Gel *in situ* Setelah Penyimpanan-Koloni Awal	-10.667	4.273	-2.497	.013	.188
Gel *in situ* Setelah Penyimpanan-Kontrol	-13.333	4.273	-3.121	.002	.027
Kontrol tetes mata Sebelum Penyimpanan- Kontrol tetes mata Setelah Penyimpanan	.000	4.273	.000	1.000	1.000
Kontrol tetes mata Sebelum Penyimpanan-Koloni Awal	-4.667	4.273	-1.092	.275	1.000
Kontrol tetes mata Sebelum Penyimpanan-Kontrol	-7.333	4.273	-1.716	.086	1.000
Kontrol tetes mata Setelah Penyimpanan-Koloni Awal	-4.667	4.273	-1.092	.275	1.000
Kontrol tetes mata Setelah Penyimpanan-Kontrol	-7.333	4.273	-1.716	.086	1.000
Koloni Awal-Kontrol	2.667	4.273	.624	.533	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.

Asymptotic significances (2-sided tests) are displayed. The significance level is .05.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.